Tiered Fixed-Dose Plerixafor Resulted in Enhanced CD34+ Cell Mobilization and Collection with a Comparable Safety Profile Versus Weight-Based Plerixafor in Patients with Sickle Cell Disease: Results from the Ongoing BEACON Study of Autologous CD34+ Base-Edited Hematopoietic Stem Cells (BEAM-101)

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Haydar Frangoul, Bahru A. Habtemariam, Arthur Lo, Srikanth Ambati, Yinzhong Chen, Sarah Chesler, Jigar Patel, Sunita Goyal, Amy Simon, Ashish O. Gupta
DOI: 10.1016/j.jtct.2025.12.921
Cited by: 1

Fields of Study & Subjects

Hematopoietic Stem Cell Transplantation Hemoglobinopathies and Related Disorders Acute Myeloid Leukemia Research

Publication details

Journal / source
Transplantation and Cellular Therapy
Publisher
Elsevier BV
Volume
32
Issue
2
Pages
S614–S615
Publication date
1 February 2026
Language
EN